Tianlong Holds Campaign for Children with Spinal Muscular Atrophy

Spinal muscular atrophy (SMA) is an inherited disease that affects the nerves and muscles, causing them to become increasingly weak. SMA affects mostly infants and children and ranks as the foremost fatal genetic disease for infants but can also develop in adults. Tianlong Science and Technology (Shaanxi, China), a leading manufacturer of molecular diagnostic products with a strong focus on social responsibility, recently held a campaign to care for children with SMA.

Tianlong offers PCR reagents covering 200 kinds of disease detection, including SMA. In addition to PCR reagents, Tianlong provides an integrated PCR lab solution from nucleic acid extractors and PCR systems to compatible reagents. Tianlong helped over 80 countries to build their healthcare systems during the COVID-19 pandemic, and the company’s nucleic acid extractors and PCR systems have been at the forefront in the fight against COVID-19. Based on the PCR melting curve method, Tianlong's Human Survival Motor Neuron 1 (SMN1) Gene Detection Kit is suitable for the auxiliary diagnosis of SMN1 patients and screening of SMN1 gene carriers.

Early detection of SMA can help with early diagnosis and treatment of the disease. In May 2022, Tianlong, in association with the SMA Care Center (a non-profit organization for SMA) in China and The Second Affiliated Hospital of Xi'an Jiaotong University, held a campaign aimed to create awareness about SMA and its early detection. During the campaign, Tianlong invited several families in China to join them in accompanying children with SMA for a day. Tianlong also hosted a lecture on SMA treatment and answered concerns of parents of children with SMA. Going forward, Tianlong will continue to work towards creating further awareness about the rare disease among people and identify more SMA children and their families. The company plans to use its advanced technologies for developing additional solutions to better care for SMA children globally.